Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunotherapy
Researchers from Kurume University, Research Center for Innovative Cancer Therapy discuss findings in immunotherapy
July 22nd, 2008
New investigation results, 'Cell- and peptide-based immunotherapeutic approaches for glioma,' are detailed in a study published in Trends In Molecular Medicine. "Glioblastoma multiforme (GBM) is the most common and lethal primary malignant brain tumor. Although considerable progress has been made in surgical and radiation treatment for glioma patients, the impact of these advances on clinical outcome has been disappointing," investigators in Kurume, Japan report. "Therefore, the development of novel therapeutic approaches is essential. Recent reports demonstrate that systemic immunotherapy using dendritic cells (DCs) or peptide vaccines is capable of inducing an...
Source: Cancer Weekly (2008-07-22)
|
